- You are viewing a Navigating Care library resource.
- Go to Library
Treatment of Recurrent Ovarian Low Malignant Potential Tumors
For information about the treatments listed below, see the Treatment Option Overview section.
Treatment for recurrent ovarian low malignant potential tumor may include the following:
- Surgery.
- Surgery followed by chemotherapy.
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
This information is not intended to replace the advice of a doctor.
Navigating Care disclaims any liability for the decisions you make based on this information.
This information was sourced and adapted from Adapted from the National Cancer Institute's
Physician Data Query (PDQ®) Cancer Information Summaries on
www.cancer.gov.
This information updated
October 1, 2024.
Learn more:
- General Information About Ovarian Low Malignant Potential Tumors
- Stages of Ovarian Low Malignant Potential Tumors
- Treatment Option Overview
- Treatment of Early Stage Ovarian Low Malignant Potential Tumors (Stage I and II)
- Treatment of Late Stage Ovarian Low Malignant Potential Tumors (Stage III and IV)
- Treatment of Recurrent Ovarian Low Malignant Potential Tumors
- To Learn More About Ovarian Low Malignant Potential Tumors
Related Articles
- General Information About Ovarian Low Malignant Potential Tumors
- Stages of Ovarian Low Malignant Potential Tumors
- Treatment Option Overview
- Treatment of Early Stage Ovarian Low Malignant Potential Tumors (Stage I and II)
- Treatment of Late Stage Ovarian Low Malignant Potential Tumors (Stage III and IV)
- Treatment of Recurrent Ovarian Low Malignant Potential Tumors
- To Learn More About Ovarian Low Malignant Potential Tumors
More Resources
See Expert Resources
The Navigating Care Library includes articles about cancer, chemotherapy regimens and drugs from the
the National Cancer Institute and other experts.
